Objective. Evaluation of the effectiveness and safety of the empegfilgrastim (Extimia®, BIOCAD) for various modes of mobilization of hematopoietic stem cells (HSCs) in patients with lymphoproliferative diseases (LPDs).
Methods. The study included 32 patients with LPDs who were treated at the National Medical Research Center for Hematology from October 2022 to April 2023. Mobilization of hematopoietic stem cells using empegfilgrastim at a dose of 7.5 mg in a “stable state of hematopoiesis” was carried out in 16 patients; and another 16 patients, drug was administered one day after polychemotherapy (PCT). A complete blood count and the blood CD34+ cell concentration at a “stable state of hematopoiesis” were estimated on the 4th and 5th days, and after the previous PCT – on the 8th and 9th days after the administration of empegfilgrastim. Leukapheresis was started if the CD34+ cell concentration exceeded 10 cells/μl, and the number of leukocytes in the blood was >5×109/l. HSC mobilization was considered effective when the CD34+ cell count was ≥2 million × 106/kg body weight. To analyze the obtained data, standard methods of descriptive statistics and frequency analysis were used.
Results. Mobilization of HSCs was effective in 20 (62.5%) of 32 patients. There were no statistically significant differences depending on the mode of HSC mobilization (P=0.76). Such factors as age, bone marrow damage, stage of the disease, presence of bulky disease, number of previous courses of chemotherapy, antitumor response status, radiation therapy, grade 3–4 anemia did not correlate with unsuccessful mobilization of HSCs. Mobilization of HSCs was more often effective in patients with Hodgkin lymphoma than in non-Hodgkin lymphomas: 55 and 25%, respectively (P=0.15).
Conclusion. The use of empegfilgrastim in a single fixed dose of 7.5 mg led to effective mobilization of HSCs in 62.5% of patients with LPDs.

Keywords: autologous transplantation, mobilization of hematopoietic stem cells, lymphoproliferative diseases, empegfilgrastim